Growth Regulation Section
$336,573ZIAFY2018CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications, trials & patents
Paper 36968141Paper 33719575Paper 33137336Paper 31133737Paper 31019291Paper 30379099Paper 28709637Paper 28266632Paper 28100250Paper 27570066Paper 27196771Paper 27187580Paper 26894650Paper 26261303Paper 26072030Paper 25962108Paper 25803818Paper 25728039Paper 25673808Paper 25587125Paper 24633808Paper 22666460Paper 22402205Paper 22234308Paper 21842266Paper 21822313Paper 21669876Paper 19898744Paper 19669888Paper 19513534Paper 19495750Paper 19250639Paper 19128473Paper 17397028Paper 17308099Paper 16585525Paper 16537515Paper 16397215Paper 16364570Paper 15798027Paper 15326299Paper 15276201Paper 15150260Paper 14981236Paper 14652002Paper 12894516Paper 12865322Paper 12746837Paper 12670487Paper 12538848Patent 9175057Patent 8043623Patent 7910692Patent 7572887Patent 7541035Patent 7410801Patent 7052703
Abstract
Mesothelin is shed from cells by the action of membrane bound proteases. We believe shedding is important for the carcinogenic effect of mesothelin. We have previously established that ADAM 17 is important for mesothelin shedding and evaluated the effect of shedding inhibitors. These only have modest activity. We have recently found that ADAM 10 may also be involved in shedding and are investigating its role in several different cancers. We have initiated a collaboration with GaloreTex to identify new mesothelin specific inhibitors which could be useful in cancer treatment.
View original record on NIH RePORTER →